Nature Communications (Jun 2022)

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

  • Sanjay Popat,
  • Stephen V. Liu,
  • Nicolas Scheuer,
  • Grace G. Hsu,
  • Alexandre Lockhart,
  • Sreeram V. Ramagopalan,
  • Frank Griesinger,
  • Vivek Subbiah

DOI
https://doi.org/10.1038/s41467-022-30908-1
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Real-world data (RWD) based control arms provide an option to compare the effectiveness of single-arm trials. By performing multiple quantitative bias analyses to alleviate concerns about trial-RWD comparability, here the authors show that the RET inhibitor pralsetinib provides survival benefit in patients with RET fusion-positive non-small cell lung cancer from the ARROW single-arm trial, (NCT03037385) when compared to pembrolizumab monotherapy and pembrolizumab with chemotherapy RWD cohorts.